Pharnext SA
PAR:ALPHA
Pharnext SA
Intangible Assets
Pharnext SA
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
Intangible Assets
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Intangible Assets
€23.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Intangible Assets
€50.3m
|
CAGR 3-Years
597%
|
CAGR 5-Years
124%
|
CAGR 10-Years
86%
|
|
|
Inventiva SA
PAR:IVA
|
Intangible Assets
€85k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Intangible Assets
$26k
|
CAGR 3-Years
23%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Intangible Assets
€6.6m
|
CAGR 3-Years
304%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's Intangible Assets?
Intangible Assets
0
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's Intangible Assets amounts to 0 EUR.
